NewAmsterdam Pharma Co NV NAMS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $21.44
- Day Range
- $21.02–22.12
- 52-Week Range
- $5.63–24.99
- Bid/Ask
- $21.92 / $21.98
- Market Cap
- $1.96 Bil
- Volume/Avg
- 62,741 / 224,188
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 128.23
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 29
Comparables
Valuation
|
Metric
|
NAMS
|
PHVS
|
QURE
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.29 | 2.88 | 1.05 |
Price/Sales | 128.23 | — | 13.72 |
Price/Cash Flow | — | — | — |
Price/Earnings
NAMS
PHVS
QURE
Financial Strength
|
Metric
|
NAMS
|
PHVS
|
QURE
|
|---|---|---|---|
Quick Ratio | 6.86 | 9.85 | 8.44 |
Current Ratio | 6.95 | 10.46 | 8.85 |
Interest Coverage | — | — | −6.85 |
Quick Ratio
NAMS
PHVS
QURE
Profitability
|
Metric
|
NAMS
|
PHVS
|
QURE
|
|---|---|---|---|
Return on Assets (Normalized) | −34.73% | −50.56% | −35.54% |
Return on Equity (Normalized) | −39.45% | −56.14% | −82.34% |
Return on Invested Capital (Normalized) | −41.57% | −56.14% | −55.12% |
Return on Assets
NAMS
PHVS
QURE
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jpdmxdzw | Kkl | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Hxgqvcd | Whklpf | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Dmvprks | Qpnckr | $97.8 Bil | |
MRNA
| Moderna Inc | Bnbjdzb | Wdmjv | $41.3 Bil | |
ARGX
| argenx SE ADR | Xqjxvmnj | Fnkzt | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Nvsxsgs | Xjqb | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Yrbgftkx | Wvgnhf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fdfwlmjr | Bhhxjgd | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Yykzbqnpr | Jwfjsx | $12.5 Bil | |
INCY
| Incyte Corp | Bsgpnzp | Lqkwc | $11.6 Bil |